In a phase II clinical trial, the TRPV1 antagonist AZD1386 failed to cause significant pain relief in patients with osteoarthritis [149,160], suggesting a more complex role for TRPV1, as well as involvement of other nociceptive channels/receptors in osteoarthritis. The gene discussed is TRPV1; the disease is osteoarthritis.